This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

This study is currently recruiting participants.
See Contacts and Locations
Verified July 2017 by Diane George, MD, Columbia University
Sponsor:
Information provided by (Responsible Party):
Diane George, MD, Columbia University
ClinicalTrials.gov Identifier:
NCT02061800
First received: February 11, 2014
Last updated: July 13, 2017
Last verified: July 2017
  Purpose

The purpose of this study is to learn more about the effects of (classification determinant) CD34+ stem cell selection on graft versus host disease (GVHD) in children, adolescents, and young adults. CD34+ stem cells are the cells that make all the types of blood cells in the body. GVHD is a condition that results from a reaction of transplanted donor T-lymphocytes (a kind of white blood cell) against the recipient's body and organs. Study subjects will be offered treatment involving the use of the CliniMACS® Reagent System (Miltenyi Biotec), a CD34+ selection device to remove T-cells from a peripheral blood stem cell transplant in order to decrease the risk of acute and chronic GVHD.

This study involves subjects who are diagnosed with a malignant disease, that has either failed standard therapy or is unlikely to be cured with standard non-transplant therapy, who will receive a peripheral blood stem cell transplant. A malignant disease includes the following: Chronic Myeloid Leukemia (CML) in chronic phase, accelerated phase or blast crisis; Acute Myelogenous Leukemia (AML); Myelodysplastic Syndrome (MDS); Juvenile Myelomonocytic Leukemia (JMML); Acute Lymphoblastic Leukemia (ALL); or Lymphoma (Hodgkin's and Non-Hodgkin's).


Condition Intervention Phase
Chronic Myeloid Leukemia (CML) Acute Myelogenous Leukemia (AML) Myelodysplastic Syndrome (MDS) Juvenile Myelomonocytic Leukemia (JMML) Acute Lymphoblastic Leukemia (ALL) Lymphoma (Hodgkin's and Non-Hodgkin's) Device: CliniMACS CD34+ Reagent System Drug: Thiotepa Drug: Cyclophosphamide Drug: Alemtuzumab Drug: Tacrolimus Drug: Melphalan Drug: Busulfan Drug: Fludarabine Drug: Methylprednisolone Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: CD34+ Stem Cell Selection for Patients Receiving a Matched or Partially Matched Family or Unrelated Adult Donor Allogeneic Stem Cell Transplant for Malignant Disease

Resource links provided by NLM:


Further study details as provided by Diane George, MD, Columbia University:

Primary Outcome Measures:
  • Incidence of acute GVHD [ Time Frame: Up to 2 years post-transplant ]
    Acute GVHD will be assessed and graded with standard NCI grading criteria.Evaluated daily while hospitalized, then weekly (1-60 days post-transplant), as clinically indicated (60-365 days post transplant), then 1 year, 1.5 years, 2 years and yearly (366+ days post-transplant)


Secondary Outcome Measures:
  • Time to neutrophil engraftment [ Time Frame: Up to 1 year post-transplant ]
    Will be assessed multiple times while hospitalized, 1-60 days post transplant, 100 days post-transplant, 180 days post-transplant, and 1-year post transplant. Neutrophil engraftment is defined as the first of three days following the neutrophil nadir with an absolute neutrophil count above 500/mm3.

  • Time to immune reconstitution [ Time Frame: Up to 2 years post-transplant ]
    Immune reconstitution studies will be conducted (For T-cell, B-cell, natural killer (NK)-cell and immunoglobulins) 60 days post-transplant, 100 days post-transplant, 150 days post-transplant, 180 days post-transplant, 270 days post-transplant, 1-year post-transplant, and 2 years post transplant.

  • Incidence of infection complications including bacterial, viral, fungal and atypical mycobacterial and other infections [ Time Frame: Up to 100 days post-transplant ]
    Will be assessed weekly or more as indicated until 84 or 100 days post-transplant, then as clinically indicated.

  • Time to platelet engraftment [ Time Frame: Up to 1 year post-transplant ]
    Will be assessed multiple times while hospitalized, 1-60 days post transplant, 100 days post-transplant, 180 days post-transplant, and 1-year post transplant.

  • Incidence of chronic GVHD [ Time Frame: Up to 2 years post-transplant ]
    Chronic GVHD will be assessed and graded with standard NCI grading criteria.

  • Severity of acute GVHD [ Time Frame: Up to 2 years post-transplant ]
    Acute GVHD will be assessed and graded with standard NCI grading criteria.

  • Severity of chronic GVHD [ Time Frame: Up to 2 years post-transplant ]
    Chronic GVHD will be assessed and graded with standard NCI grading criteria. Evaluated daily while hospitalized, then weekly (1-60 days post-transplant), as clinically indicated (60-365 days post transplant), then 1 year, 1.5 years, 2

  • Incidence of primary graft failure [ Time Frame: 42 (or more) days post-transplant ]
    Primary graft rejection is defined as the presence of < 20% donor cells

  • Incidence of secondary graft failure [ Time Frame: 42 (or more) days post-transplant ]
    The presence of < 20% donor derived hematopoietic cells in peripheral blood


Estimated Enrollment: 25
Actual Study Start Date: June 3, 2013
Estimated Study Completion Date: December 2018
Estimated Primary Completion Date: December 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Full intensity with TBI
Patients will start their pre-conditioning regimen on 8 days before scheduled transplant. Fractionated total body irradiation (TBI) will be administered twice daily on the 6th, 7th, and 8th before transplant. Patients will receive Thiotepa on the 4th and 5th day before transplant, Cyclophosphamide on the 2nd and 3rd day before transplant, and Alemtuzumab on the 1st-5th day(s) before transplant. Then the stem cell infusion will be performed (allogeneic family member or ≥ 8/10 HLA matched adult unrelated donor peripheral blood stem cell transplantation with CD34 Selection using CliniMACS CD34+ Reagent System). GVHD prophylaxis will consist of tacrolimus only. Tacrolimus administration will begin on the day after transplant, and methylprednisolone will start on day -5.
Device: CliniMACS CD34+ Reagent System
The CliniMACS® Reagent System (Miltenyi Biotec, Germany), is a semi-automated immunomagnetic cell selection medical device that is used in vitro to select and enrich specific cell populations in a closed, sterile environment. The system is comprised of a computer controlled medical device containing a permanent magnet, a closed-system sterile tubing set containing columns coated with a ferromagnetic matrix, and a magnetic cell specific labeling reagent.
Drug: Thiotepa
Standard of care: Thiotepa should be diluted in normal saline (NS) (1-5 mg/ml) and infused over 2 hrs on Days -5, -4. IV fluids should be at maintenance rate (1500 ml/m2). It is recommended that total parental nutrition not being used during Thiotepa administration as amino acid infusions may interfere with Thiotepa metabolism.
Other Name: Thioplex
Drug: Cyclophosphamide
Standard of care: Cyclophosphamide (Cytoxan) should be infused over one hour. The drug can be diluted in dextrose water solvent (D5W), NS, or other solutions (250cc) to a maximum concentration of 20 mg/mL.
Other Name: Cytoxan
Drug: Alemtuzumab
Standard of care: Each dose of alemtuzumab is to be diluted in D5W or NS (maximum concentration: 0.3 mg/mL) for IV infusion over two hours.
Other Name: Campath
Drug: Tacrolimus
Standard of care: Tacrolimus dosing will be 0.03mg/kg/24 hours as continuous IV infusion or 0.12 mg/kg/day po divided Q8-12 hr
Other Names:
  • Prograf
  • FK506
Drug: Methylprednisolone
Standard of care: Methylprednisolone will be give IV slow infusion over 15-30 minutes.
Other Name: Solu-Medrol
Experimental: Full intensity without TBI
Patients will start their pre-conditioning regimen 9 days before their scheduled transplant. Patients will receive busulfan twice daily on the 5th-8th day before transplant, and Melphalan on the 2nd-4th days before transplant and Alemtuzumab on the 1st-5th day before transplant. Subjects will then undergo with their stem cell infusion (allogeneic family member or ≥ 8/10 HLA matched adult unrelated donor peripheral blood stem cell transplantation with CD34 Selection using CliniMACS CD34+ Reagent System) and GVHD prophylaxis will consist of tacrolimus only. Tacrolimus administration will begin on the day after their transplant, and methylprednisolone will start on day -5.
Device: CliniMACS CD34+ Reagent System
The CliniMACS® Reagent System (Miltenyi Biotec, Germany), is a semi-automated immunomagnetic cell selection medical device that is used in vitro to select and enrich specific cell populations in a closed, sterile environment. The system is comprised of a computer controlled medical device containing a permanent magnet, a closed-system sterile tubing set containing columns coated with a ferromagnetic matrix, and a magnetic cell specific labeling reagent.
Drug: Alemtuzumab
Standard of care: Each dose of alemtuzumab is to be diluted in D5W or NS (maximum concentration: 0.3 mg/mL) for IV infusion over two hours.
Other Name: Campath
Drug: Tacrolimus
Standard of care: Tacrolimus dosing will be 0.03mg/kg/24 hours as continuous IV infusion or 0.12 mg/kg/day po divided Q8-12 hr
Other Names:
  • Prograf
  • FK506
Drug: Melphalan
Standard of care: Melphalan 45mg/m2 (1.5 mg/kg IV for children <1 year of age or <10 kg) diluted in 0.9% NS to a concentration of 0.1- 0.45mg/ml, given IV over 30 minutes.
Other Name: Alkeran
Drug: Busulfan
Standard of care: Busulfan will be given IV in 0.9% sodium chloride or D5W to a final solution for infusion equal to 10 times the volume of diluent to Busulfex (to a concentration >0.5 mg/mL), through a central venous access device over 2 hours.
Other Name: Busulfex
Drug: Methylprednisolone
Standard of care: Methylprednisolone will be give IV slow infusion over 15-30 minutes.
Other Name: Solu-Medrol
Experimental: Reduced intensity
Patients will begin tacrolimus 8 days pre-transplant, and then will receive alemtuzumab on the 3rd-7th day pre-transplant; busulfan twice daily on the 5th-8th day pre-transplant; and fludarabine on the 2nd-7th day pre-transplant. Methylprednisolone will start on day -7.The stem cell infusion will be performed (with CD34 Selection using CliniMACS CD34+ Reagent System). GVHD prophylaxis will consist of tacrolimus or sirolimus. For patients with a history of hepatic toxicity and/or high-risk for veno-occlusive disease or other liver toxicity post stem cell transplant, melphalan at 70 mg/m2 will be substituted for Busulfan, followed by fludarabine on the 2nd-7th day before transplant and alemtuzumab on the 3rd-7th day before transplant.
Device: CliniMACS CD34+ Reagent System
The CliniMACS® Reagent System (Miltenyi Biotec, Germany), is a semi-automated immunomagnetic cell selection medical device that is used in vitro to select and enrich specific cell populations in a closed, sterile environment. The system is comprised of a computer controlled medical device containing a permanent magnet, a closed-system sterile tubing set containing columns coated with a ferromagnetic matrix, and a magnetic cell specific labeling reagent.
Drug: Alemtuzumab
Standard of care: Each dose of alemtuzumab is to be diluted in D5W or NS (maximum concentration: 0.3 mg/mL) for IV infusion over two hours.
Other Name: Campath
Drug: Tacrolimus
Standard of care: Tacrolimus dosing will be 0.03mg/kg/24 hours as continuous IV infusion or 0.12 mg/kg/day po divided Q8-12 hr
Other Names:
  • Prograf
  • FK506
Drug: Busulfan
Standard of care: Busulfan will be given IV in 0.9% sodium chloride or D5W to a final solution for infusion equal to 10 times the volume of diluent to Busulfex (to a concentration >0.5 mg/mL), through a central venous access device over 2 hours.
Other Name: Busulfex
Drug: Fludarabine
Standard of care: Fludarabine will be given IV in 50-100 ml of D5W or 0.9% sodium chloride, over 30 minutes.
Other Name: Fludara
Drug: Methylprednisolone
Standard of care: Methylprednisolone will be give IV slow infusion over 15-30 minutes.
Other Name: Solu-Medrol

Detailed Description:
Graft versus host disease (GVHD) is one of the serious complications following allogeneic stem cell transplantation. The incidence and severity of GVHD increase with the degree of HLA incompatibility between the host and donor. The most reliable way to prevent acute and chronic GVHD is to remove T cells from the graft. However, the incidence of graft failure increases with the efficiency of T cell depletion and low T cell numbers are predictive of graft failure. Immunomagnetic selection of HLA-mismatched CD34+ progenitor cells has demonstrated high levels of T cell depletion and successful engraftment in adult and pediatric patients with the malignant and nonmalignant disease.
  Eligibility

Ages Eligible for Study:   up to 22 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria: General Eligibility (All Patients)

  • Must be < 22 years of age
  • Diagnosed with a malignant disease
  • Must be fully informed about their illness and the investigational nature of the study protocol (including foreseeable risks and possible side effects), and must sign an informed consent
  • For unrelated donor: A human leukocyte antigen (HLA) 8/10, 9/10 or 10/10 matched unrelated adult donor (MUD) will be required for study entry
  • For related donor: A 5/10, 6/10, 7/10, 8/10, 9/10 or 10/10 matched (or partially matched) family donor will be required for study entry
  • Adequate renal function
  • Adequate liver function
  • Adequate cardiac function
  • Adequate pulmonary function

Exclusion Criteria:

  • Patients with documented uncontrolled infection at the time of study entry are not eligible
  • Females who are pregnant or breast feeding at the time of study entry are not eligible
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02061800

Contacts
Contact: Jean Sosna, RN 212-305-2050 js4403@columbia.edu

Locations
United States, New York
Columbia University Medical Center Recruiting
New York, New York, United States, 10032
Contact: Jean Sosna, RN    212-305-2050      
Principal Investigator: Diane George, MD         
Sponsors and Collaborators
Diane George, MD
Investigators
Principal Investigator: Diane George, MD Columbia University
  More Information

Responsible Party: Diane George, MD, Assistant Professor of Pediatrics, Department of Pediatrics Onc/BMT/Hem, Columbia University
ClinicalTrials.gov Identifier: NCT02061800     History of Changes
Other Study ID Numbers: AAAK8060
Study First Received: February 11, 2014
Last Updated: July 13, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Diane George, MD, Columbia University:
Unrelated donor transplant
Allogenic Stem Cell Transplant
Adult Bone Marrow Transplant
Pediatric Bone Marrow Transplant
Related donor transplant
Haploidentical donor transplant
Peripheral blood stem cell transplantation
Non-malignant disease
Malignant disease
Bone marrow failure syndrome
Severe Aplastic Anemia
Severe Congenital Neutropenia
Amegakaryocytic Thrombocytopenia
Diamond-Blackfan Anemia
Schwachman Diamond Syndrome
Primary Immunodeficiency Syndrome
Acquired Immunodeficiency Syndrome
Histiocytic Syndrome
Familial Hemophagocytic Lymphocytosis
Lymphohistiocytosis
Macrophage Activation Syndrome
Langerhans Cell Histiocytosis (LCH)
Hemoglobinopathies
Reduced-Intensity Conditioning
Sickle Cell Disease
Sickle Cell-beta-thalassemia

Additional relevant MeSH terms:
Syndrome
Leukemia
Myelodysplastic Syndromes
Preleukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Leukemia, Myeloid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid, Acute
Leukemia, Myelomonocytic, Juvenile
Lymphoma
Disease
Pathologic Processes
Neoplasms by Histologic Type
Neoplasms
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Myeloproliferative Disorders
Myelodysplastic-Myeloproliferative Diseases
Cyclophosphamide
Tacrolimus
Fludarabine phosphate
Melphalan
Busulfan
Thiotepa

ClinicalTrials.gov processed this record on August 23, 2017